1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
17多系統萎縮症3

17. 多系統萎縮症

臨床試験数 : 119 /  薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2014-004902-13-SE
(EUCTR)		14/04/201502/01/2015Study to assess the effect of AZD3241 in Multiple System AtrophyA 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy Multiple system atrophy (MSA)
MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: AZD3241 100mg
Product Code: AZD3241
INN or Proposed INN: Not available
Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one
Product Name: AZD3241 300mg
Product Code: AZD3241
INN or Proposed INN: Not available
Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one		AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes		64Phase 2France;United States;Finland;Austria;Italy;United Kingdom;Sweden
2EUCTR2014-004902-13-GB
(EUCTR)		09/04/201524/12/2014Study to assess the effect of AZD3241 in Multiple System AtrophyA 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy Multiple system atrophy (MSA)
MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: AZD3241 100mg
Product Code: AZD3241
INN or Proposed INN: Not available
Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one
Product Name: AZD3241 300mg
Product Code: AZD3241
INN or Proposed INN: Not available
Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one		AstraZeneca ABNULLNot Recruiting Female: yes
Male: yes		64 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Finland;United Kingdom;Sweden
3EUCTR2014-004902-13-FI
(EUCTR)		11/02/201531/12/2014Study to assess the effect of AZD3241 in Multiple System AtrophyA 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy Multiple system atrophy (MSA)
MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: AZD3241 100mg
Product Code: AZD3241
INN or Proposed INN: Not available
Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one
Product Name: AZD3241 300mg
Product Code: AZD3241
INN or Proposed INN: Not available
Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one		AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes		64Phase 2United States;France;Finland;Austria;United Kingdom;Italy;Sweden